Indian Journal of Critical Care Medicine

Register      Login



Volume / Issue

Online First

Related articles

VOLUME 28 , ISSUE 5 ( May, 2024 ) > List of Articles

Original Article

Clinical Utility of Blood Culture Identification 2 Panel in Flagged Blood Culture Samples from the Intensive Care Unit of a Tertiary Care Hospital

Vashemane K Vineeth, Panchatcharam S Nambi, Ram Gopalakrishnan, Nandini Sethuraman, Yamunadevi Ramanathan, Chitra Chandran, Venkatasubramanian Ramasubramanian

Keywords : Antimicrobial stewardship, Blood culture identification 2, Flagged cultures, Polymyxin

Citation Information : Vineeth VK, Nambi PS, Gopalakrishnan R, Sethuraman N, Ramanathan Y, Chandran C, Ramasubramanian V. Clinical Utility of Blood Culture Identification 2 Panel in Flagged Blood Culture Samples from the Intensive Care Unit of a Tertiary Care Hospital. Indian J Crit Care Med 2024; 28 (5):461-466.

DOI: 10.5005/jp-journals-10071-24709

License: CC BY-NC 4.0

Published Online: 30-04-2024

Copyright Statement:  Copyright © 2024; The Author(s).


Background: The availability of rapid diagnostic platforms for positive blood cultures has accelerated the speed at which the clinical microbiology laboratory can identify the causative organism and facilitate early appropriate antimicrobial therapy. There is a paucity of data regarding the clinical utility of the blood culture identification 2 (BCID2) panel test and its correlation with phenotypic drug susceptibility testing (DST) in flagged blood culture bottles from intensive care units (ICUs) in countries such as India, which have high rates of multidrug-resistant gram-negative bacteria (MDR-GNB). Materials and methods: We conducted a retrospective observational study in a tertiary care ICU on 200 patients above 18 years of age in whom a BCID2 test was ordered when blood cultures flagged positive. Results: We found 99% concordance between BCID2 and cultures in the identification of bacteria and yeasts and 96.5% concordance between phenotypic and genotypic DST. Furthermore, BCID2 was available about 1.5 days earlier than conventional ID and DST and played a key role in tailoring antimicrobials in 82.5% of the patients. Polymyxin-based therapy was discontinued earlier after an empiric dose in 138 patients (69%) based on BCID2 reports. Conclusion: In critically ill patients with monomicrobial bacteremia, BCID2 rapidly identifies bacteria and antimicrobial resistance (AMR) genes and is significantly faster than conventional culture and sensitivity testing. Antibiotics were escalated in more than a third of patients and de-escalated in almost a fifth on the same day. We recommend that all ICUs routinely incorporate the test in their antibiotic decision-making process and in antimicrobial stewardship.

PDF Share
  1. Evans L, Rhodes A, Alhazzani W, Antonelli M, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. Crit Care Med 2021;49(11):e1063–e1143. DOI: 10.1097/CCM.0000000000005337.
  2. Murrray Ji, Ikuta S, Sharara F, et al. Antimicrobial Resistance Collaborators, Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis. Lancet 2022;399(10325):629–655. DOI: 10.1016/S0140-6736(21)02724-0.
  3. Altun O, Almuhayawi M, Ullberg M, Ozenci V. Clinical evaluation of the FilmArray blood culture identification panel in identification of bacteria and yeasts from positive blood culture bottles. J Clin Microbiol 2013;51(12):4130–4136. DOI: 10.1128/JCM. 01835-13.
  4. Ramanathan YV, Arjun R, Krishna V, Tarigopula A, Gopalakrishnan R. Multiplex polymerase chain reaction (PCR) for rapid bacterial identification from blood cultures: Ready for prime time in India? J Contemp Clin Pract 2019;5(1):24–30. DOI: 10.18683/jccp.2019. 1042.
  5. Arjun R, Niyas VKM, John KE, Nair A, Hussain F. Impact of adding Rapid Polymerase Chain Reaction-based Blood Culture Identification Panel to Antimicrobial Stewardship Program: Initial Experience. Indian J Crit Care Med 2022;26(10):1155–1157. DOI: 10.5005/jp-journals-10071-24329.
  6. Humphries R, Bobenchik AM, Hindler JA, Schuetz AN. Overview of Changes to the Clinical and Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing, M100, 31st Edition. J Clin Microbiol 2021;59(12):e0021321. DOI: 10.1128/JCM.00213-21.
  7. Tabah A, Bassetti M, Kollef MH, Zahar JR, Paiva JA, Timsit JF, et al. Antimicrobial de-escalation in critically ill patients: A position statement from a task force of the European Society of Intensive Care Medicine (ESICM) and European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Critically Ill Patients Study Group (ESGCIP), Intensive Care Med 2020;46(2):245–265. DOI: 10.1007/s00134-019-05866.
  8. Porwal R, Gopalakrishnan R, Rajesh NJ, Ramasubramanian V. Carbapenem resistant Gram-negative bacteremia in an Indian intensive care unit: A review of the clinical profile and treatment outcome of 50 patients. Indian J Crit Care Med 2014;18(11):750-753. DOI: 10.4103/0972-5229.144021.
  9. Alagesan M, Gopalakrishnan R, Panchatcharam SN, Dorairajan S, Mandayam Ananth T, Venkatasubramanian R. A decade of change in susceptibility patterns of Gram-negative blood culture isolates: a single center study. Germs 2015;5(3):65–77. Published 2015 Sep 1. DOI: 10.11599/germs.2015.1073.
  10. Sisay M, Hagos B, Edessa D, Tadiwos Y, Mekuria AN. Polymyxin-induced nephrotoxicity and its predictors: A systematic review and meta-analysis of studies conducted using RIFLE criteria of acute kidney injury. Pharmacol Res 2021;163:105328. DOI: 10.1016/j.phrs.2020.105328.
  11. Shah S, Davar N, Thakkar P, Swant C, Jadhav L. Clinical utility of the FilmArray blood culture identification 2 panel in identification of microorganisms and resistance markers from positive blood culture bottles. Indian J Microbiol Res 2022;9(1):28–33. DOI: 10.18231/j.ijmr.2022.005.
  12. Peri AM, Bauer MJ, Bergh H, Butkiewicz D, Paterson DL, Harris PN. Performance of the BioFire Blood Culture Identification 2 panel for the diagnosis of bloodstream infections. Heliyon 2022;8(7):e09983. DOI: 10.1016/j.heliyon.2022.e09983.
  13. Berinson B, Both A, Berneking L, Christner M, Lütgehetmann M, Aepfelbacher M, et al. Usefulness of BioFireFilmArray BCID2 for Blood Culture Processing in Clinical Practice. J ClinMicrobiol 2021;59(8):e0054321. DOI: 10.1128/JCM.00543-21.
  14. Rajendran S, Gopalakrishnan R, Tarigopula A, Kumar DS, Nambi PS, Sethuraman N, et al. Clinical Utility in Intensive Care Unit Patients with Bacteremia Caused by Enterobacteriaceae. Indian J Crit Care Med 2023;27(9):655–662. DOI: 10.5005/jp-journals-10071-24533.
  15. Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections. Clin Infect Dis 2023:ciad428. DOI: 10.1093/cid/ciad428.
  16. Codjoe FS, Donkor ES. Carbapenem Resistance: A Review. Med Sci (Basel) 2017;6(1):1. DOI: 10.3390/medsci6010001.
  17. El Chakhtoura NG, Saade E, Iovleva A, Yasmin M, Wilson B, Perez F, et al. Therapies for multidrug resistant and extensively drug-resistant non-fermenting gram-negative bacteria causing nosocomial infections: A perilous journey toward ‘molecularly targeted’ therapy. Expert Rev Anti Infect Ther 2018;16(2):89–110. DOI: 10.1080/14787210.2018.1425139.
  18. Yoon EJ, Jeong SH. Mobile Carbapenemase Genes in Pseudomonas aeruginosa. Front Microbiol 2021;12:614058. DOI: 10.3389/fmicb. 2021.614058.
  19. Ismail B, Shafei MN, Harun A, Ali S, Omar M, Deris ZZ. Predictors of polymyxin B treatment failure in Gram-negative healthcare-associated infections among critically ill patients. J Microbiol Immunol Infect 2018;51(6):763–769. DOI: 10.1016/j.jmii.2017. 03.007.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.